DIAGNOSIS OF BACTERIAL COMPLICATIONS IN COVID-19-ASSOCIATED PNEUMONIA
Keywords:
Covid-19-associated pneumonia, diagnosis, prognosis, bacterial complications, antibiotics, SARS-CoV-2Abstract
Bacterial complications of COVID-19 are very common and directly impact the severity and outcome of the disease. This study identified a spectrum of clinically significant bacterial pathogens in samples collected from patients with COVID-19 associated pneumonia, as well as obtained data on the sensitivity of antibiotics to isolated pathogens. The results of antibiotic susceptibility testing of isolates isolated from patients allowed us to develop evidence-based recommendations for the selection of empirical antibacterial therapy for patients with COVID-19 associated pneumonia. Secondary bacterial infection with the SARS-CoV-2 virus is rare, so in outpatient practice, antibacterial agents should not be prescribed unjustifiably, and overdiagnosis and polypharmacy should be avoided. However, patients hospitalized in hospitals need to be given special attention to prevent the development of nosocomial infections, including COVID-19.
References
Garg, S. (2020). Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed coronavirus disease 2019-COVID-NET, 14 States, March 1–30, 2020. MMWR. Morbidity and mortality weekly report, 69. (in Russ).
Yupatov, E. Yu., Kurmanbaev, T. E., & Timoshkova, Yu. L. (2022). Current understanding of vascular endothelial function and dysfunction. Literature review. RMJ, 30(3), 20-23.
Zaitsev, A. A. (2021). Non-severe community-acquired pneumonia. RMJ, 29(3), 19-23.
Cao, Y. (2021, October). The impact of the hypoxia‐VEGF‐vascular permeability on COVID‐19‐infected patients. In Exploration (Vol. 1, No. 2, p. 20210051).
Glybochko, P. V., Fomin, V. V., Avdeev, S. N., Moiseev, S. V., Yavorovsky, A. G., Brovko, M. Yu., & Yakovleva, A. A. (2020). Clinical characteristics of 1007 patients with severe SARS-CoV-2 pneumonia who required respiratory support. Clinical Pharmacology and Therapeutics, 29(2), 21-29.
Arastehfar, A., Carvalho, A., van de Veerdonk, F. L., Jenks, J. D., Koehler, P., Krause, R., & Hoenigl, M. (2020). COVID-19 associated pulmonary aspergillosis (CAPA)-from immunology to treatment. Journal of Fungi, 6(2), 91.
Sinopalnikov Alexander Igorevich (2021). The COVID-19 "pandemic" of antibacterial therapy. Clinical Microbiology and Antimicrobial Chemotherapy, 23 (1), 5-15.
Alkodaymi, M. S., Omrani, O. A., Ashraf, N., Abou Shaar, B., Almamlouk, R., Riaz, M., ... & Tleyjeh, I. M. (2022). Prevalence of post-acute COVID-19 syndrome symptoms at different follow-up periods: a systematic review and meta-analysis. Clinical Microbiology and Infection, 28(5), 657-666.
Hajibeygi , R., Mirghazanfari , S. M., Pahlavani , N., Jalil, A. T., Alshahrani , S. H., Rizaev , J. A., ... & Yekta , N. H. (2022). Effect of a diet based on Iranian traditional medicine on inflammatory markers and clinical outcomes in COVID-19 patients: A double-blind, randomized, controlled trial. European Journal of Integrative Medicine, 102179.
Zeynitdinova , Z. A. , RIZAEV , J. A. , & Oripov , F. WITH . (2022). The degree of cytological damage to the epithelium of the buccal mucosa in COVID-19. JOURNAL OF BIOMEDICINE AND PRACTICE, 7(2).
Umirzakov Zokir , Rizaev Jasur , UMIROV Safar . The phenomenon of the epidemic
covid-19 process and their leading determinants. Journal of Biomedicine and Practice. 2021, vol . 6, issue 6, pp . 286-295
Rizaev , woman A., Kushakov, B. Zh., Rustamova , D. A. (2022). Manifestations of coronavirus infection SARS-COV-2 in the oral cavity. Journal of Biomedicine and Practice, 7(2).
Umirzakov , Z., Rizaev , Zh., Umirov , S., & Rustamova , D. (2022). ORGANIZATION OF MEDICAL SERVICES IN THE COVID-19 EPIDEMIC CENTER. Journal of Dentistry and Craniofacial Research, 2(3), 67–73. https://doi.org/10.26739.2181-0966-2021-3-13
